SynthesisHeadache2026
Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.
Synthesis in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.Headache · 2026Pooled it
- ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.Brain and behavior · 2026Article
- Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024.The journal of headache and pain · 2026Article
- Migraine Prevalence and QALY Loss in Serbia: A Population-Level Stratified Modeling Study.Risk management and healthcare policy · 2026Article
- Potential Roles of G Protein-Coupled Receptor 30 (GPR30) in Migraine Pathophysiology.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to summarize and pool real-world evidence on the clinical effectiveness and safety of galcanezumab.
backgroundMigraine is a disabling primary headache disorder. Several drugs that target calcitonin gene-related peptide, such as galcanezumab, have recently been developed. However, real-world effects have not been well studied.
methodsA systematic search of PubMed, Scopus, and Web of Science was conducted from inception to February 2025. Studies that estimated the real-world effects of galcanezumab on monthly migraine days (MMDs), monthly headache days (MHDs), Headache Impact Test, Migraine Disability Assessment Scale, number of days in medication, acute monthly intake (AMI), pain intensity, and safety outcomes were included. Meta-analyses of proportions or mean differences were performed.
resultsThirty-six studies were included, with an agreement of 0.93 [95% confidence interval (CI): 0.90, 0.96]. One month after the first injection, the reduction effects were -6.93 days (95% CI: -7.88, -5.99) for MMD, -8.55 days (95% CI: -11.32, -5.78) for MHD, and -7.96 points (95% CI: -8.93, -6.99) for Headache Impact Test. Over 60% of patients achieved a reduction in MMD/MHD of at least 50% within 3 months. The effect increased gradually and slightly up to 12 months. The adverse event rates were 0.25 (95% CI: 0.14, 0.38) and 0.35 (95% CI: 0.27, 0.45) at 6 and 12 months, respectively, with constipation being the most common.
conclusionGalcanezumab appears to be associated with clinically meaningful improvements in migraine and favorable safety outcomes, although the evidence certainty is limited by heterogeneity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.